The West Australian Intravenous Minocycline and TPA Stroke Study (WAIMATSS) [17] is a multicentre, prospective, and randomised pilot study of intravenous minocycline, 200 mg 12 hourly for 5 doses, compared with standard care, in patients with ischaemic stroke treated with intravenous tissue plasminogen activator (tPA). The gene discussed is PLAT; the disease is ischemic stroke.